Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca announced that Aradhana Sarin, the Executive Director and Chief Financial Officer, sold 9,563 of the company’s ordinary shares on August 14, 2025, at a price of £115.117 per share. This transaction is part of the company’s regulatory compliance with the EU Market Abuse Regulation, reflecting internal managerial decisions that might influence stakeholder perceptions and market dynamics.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and strategic investments in R&D and manufacturing are significant strengths. Positive technical indicators and robust earnings call insights further support the stock’s potential. However, high valuation metrics and cash flow management challenges slightly temper the overall score.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
Average Trading Volume: 2,293,855
Technical Sentiment Signal: Strong Buy
Current Market Cap: £179.7B
For a thorough assessment of AZN stock, go to TipRanks’ Stock Analysis page.